US EditionOricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
The financing will support global trials and manufacturing as Oricell advances Ori-C101 toward pivotal development for solid tumors and blood cancers.
- On Friday, April 10, 2026, Oricell Therapeutics Holdings Limited announced the closing of a pre-IPO financing round exceeding $110 million, marking a major milestone ahead of its public market debut.
- Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, and Qiming Venture Partners co-led the financing, with participation from NGS Super, E-Town Capital, Elikon Investment, and Talon Capital.
- Oricell leverages a proprietary technology triad—Ori-Ab, Ori-Armoring, and OnGo CMC—to engineer CAR-T therapies targeting solid tumors and hematologic malignancies across its pipeline.
- Chairman and CEO Huanfeng Yang stated the priority is to "expedite the global development of our core assets," including Ori-C101 and OriCAR-017, using the new capital.
- Vivo Capital Managing Partner Shan Fu noted Oricell distinguishes itself with "best-in-class clinical data," positioning the firm to set a new standard of care in cell therapy.
39 Articles
39 Articles
Bennington Banner
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
SHANGHAI, April 9, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by…
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies - PressReach
SHANGHAI, April 9, 2026 /PRNewswire/ — Oricell Therapeutics Holdings Limited (“Oricell”), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate…
China-based CAR-T company Oricell raises $40M more as it looks to go public
Oricell Therapeutics has raised more than $110 million in what it calls a pre-IPO financing. The company is developing CAR-T therapies for solid tumors, including a GPC3-targeted autologous CAR-T therapy for a type of liver cancer.
Oricell Therapeutics raises $110 million for solid tumor CAR-T
SHANGHAI, April 10, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndica…
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
